Apply to trial NCT03854110

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Trial to Evaluate Safety and Tolerability of Misetionamide (GP-2250) in Combination With Gemcitabine

This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy completed enrolment.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Trial to Evaluate Safety and Tolerability of Misetionamide (GP-2250) in Combination With Gemcitabine

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening